Get the Stockscreener App
6.85
0.29%
-0.02
After Hours:
6.82
-0.03
-0.44%
Kamada Ltd stock is traded at $6.85, with a volume of 26,618.
It is down -0.29% in the last 24 hours and up +3.79% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$6.87
Open:
$6.9715
24h Volume:
26,618
Relative Volume:
0.26
Market Cap:
$393.94M
Revenue:
$154.57M
Net Income/Loss:
$15.07M
P/E Ratio:
25.37
EPS:
0.27
Net Cash Flow:
$10.92M
1W Performance:
+3.32%
1M Performance:
+3.79%
6M Performance:
+16.30%
1Y Performance:
+31.23%
1-Day Range:
$6.78
$6.9715
1-Week Range:
$6.78
$7.0568
52-Week Range:
$4.74
$9.155
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
6.85 | 381.26M | 154.57M | 15.07M | 10.92M | 0.27 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | The Benchmark Company | Buy |
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Alpha-1 Antitrypsin Deficiency Market: Epidemiology, - openPR.com
Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Kamada (NASDAQ:KMDA) Stock Rating Upgraded by Wall Street Zen - Defense World
Kamada's (TLV:KMDA) Solid Earnings Are Supported By Other Strong Factors - simplywall.st
HC Wainwright Issues Optimistic Outlook for Kamada Earnings - Defense World
Sidoti Csr Has Optimistic Outlook of Kamada FY2025 Earnings - Defense World
Kamada’s (KMDA) Buy Rating Reiterated at Benchmark - Defense World
Kamada Ltd. (NASDAQ:KMDA) Q1 2025 Earnings Call Transcript - MSN
Is Kamada (KMDA) Stock Undervalued Right Now? - Yahoo Finance
Kamada Ltd’s Earnings Call Highlights Strong Growth and Expansion - TipRanks
Kamada (KMDA) Receives Reiterated Buy Rating from Benchmark | KM - GuruFocus
Kamada (KMDA) Receives Reiterated Buy Rating from Benchmark | KMDA Stock News - GuruFocus
Benchmark maintains Kamada stock Buy rating with $15 target By Investing.com - Investing.com Nigeria
Kamada: Q1 Earnings Snapshot - CT Insider
Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - Yahoo
Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Kamada Ltd. Reports Strong Q1 2025 Results - TipRanks
Kamada Q1 2025 Earnings Call Transcript - MarketBeat
Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Kamada Reports Strong First Quarter 2025 Financial Results with - GuruFocus
Kamada Reports Strong Q1 2025 Financial Results and Expands Plasma Operations - TipRanks
Kamada Reports Strong First Quarter 2025 Financial Results - GlobeNewswire
Inter Alpha Inhibitor Treatment Market Size in 7MM is expected - openPR.com
Kamada (KMDA) Projected to Post Quarterly Earnings on Wednesday - Defense World
Kamada (NASDAQ:KMDA) Upgraded at Sidoti - Defense World
Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025 - GlobeNewswire
Kamada Ltd. to report Q1 2025 financial results on May 14 - Investing.com Nigeria
Kamada to Release Q1 2025 Financial Results on May 14 - TipRanks
JPMorgan Chase & Co. Invests $67,000 in Kamada Ltd. (NASDAQ:KMDA) - Defense World
Kamada Launches Post-Marketing Research Program for CYTOGAM - TipRanks
Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM® - GlobeNewswire
Major Breakthrough: Kamada Initiates 10 Clinical Studies to Transform Organ Transplant CMV Treatment - Stock Titan
Geode Capital Management LLC Raises Position in Kamada Ltd. (NASDAQ:KMDA) - Defense World
Kamada Ltd expected to post earnings of 7 cents a shareEarnings Preview - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Kamada Expands Specialty Plasma Collection Capabilities with New San Antonio Facility - citybuzz -
Kamada Expects Third Plasma Collection Site To Support Its Hyper-Immune Plasma Needs And Add Up To $10M In Annual Revenue At Full Capacity - The Globe and Mail
Renaissance Technologies LLC Lowers Holdings in Kamada Ltd. (NASDAQ:KMDA) - Defense World
Kamada Is Bringing Relief To Those With Rare And Serious ConditionsKamada (NASDAQ:KMDA) - Benzinga
Despite shrinking by ₪175m in the past week, Kamada (TLV:KMDA) shareholders are still up 21% over 3 years - simplywall.st
Kamada Ekadashi 2025: Know the date, timings, significance, puja vidhi, and more - The Indian Express
Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 61.8% in March - MarketBeat
Kamada (NASDAQ:KMDA) Downgraded by StockNews.com to “Buy” - Defense World
Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders - GlobeNewswire
Kamada Ltd. announces dividend tax details By Investing.com - Investing.com Australia
Kamada Ltd. announces dividend tax details - Investing.com
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
18.36%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):